Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Looks interesting... I've been trying to find an investment in that area. Weed.
Looks like we should have been tracking the medical marijuana stocks on this board
I've followed OPKO for several years. I think the big money has been made in this one. But, Phil Frost could still sell it at a premium. I would look at some of his other holdings.
I really don't know any thing about that stock.
FRANKLIN, Tenn.--(BUSINESS WIRE)--Community Health Systems, Inc. (NYSE: CYH) (“CHS”) announced today that it has completed its previously announced acquisition of Health Management Associates, Inc. (NYSE: HMA) (“HMA”).
“We are very pleased to complete this important strategic acquisition and welcome our newly affiliated hospitals and their physicians and employees to our organization”
“We are very pleased to complete this important strategic acquisition and welcome our newly affiliated hospitals and their physicians and employees to our organization,” said Wayne T. Smith, Chairman and Chief Executive Officer of Community Health Systems, Inc. “This transaction provides us with increased scale and broader geographic reach as we work to create strong healthcare networks across the nation. Our larger organization is well positioned to address the changing dynamics in our industry and dedicated to providing quality care for millions of patients and all the communities we serve. We look forward to effectively integrating this acquisition and generating significant value for our shareholders.”
Effective today, HMA will cease trading on the New York Stock Exchange. HMA shareholders will receive $10.50 per share in cash plus 0.06942 shares of CHS common stock for each HMA share they own. HMA shareholders will also receive one Contingent Value Right (CVR) for each HMA share they own, which could yield additional cash consideration of up to $1.00 per share, depending on the outcome of certain matters described in HMA’s public filings under the “Legal Proceedings” section.
Through its affiliates, Community Health Systems now owns, leases or operates 206 hospitals in 29 states. The organization’s affiliates employ more than 135,000 people and approximately 27,000 physicians serve on the medical staffs of CHS-affiliated hospitals. CHS’s headquarters will remain in the Nashville, Tennessee, suburb of Franklin.
About CHS
Community Health Systems, Inc. is one of the largest publicly-traded hospital companies in the United States and a leading operator of general acute care hospitals in communities across the country. Through its subsidiaries, the Company currently owns, leases or operates 206 affiliated hospitals in 29 states with an aggregate of approximately 31,000 licensed beds. The Company’s headquarters are located in Franklin, Tennessee, a suburb south of Nashville. Shares in Community Health Systems, Inc. are traded on the New York Stock Exchange under the symbol “CYH.” More information about the Company can be found on its website at www.chs.net.
Joeysco,
I can across CYHHZ this morning.I am not sure if it is a buy.Maybe, one to watch.
BACKGROUND
On January 8, 2014, Shareholders of Health Management Associates, Inc. (HMA) voted concerning the
proposed merger with Community Health Systems, Inc. (CYH). The merger was approved and was
consummated before the open on January 27, 2014. As a result, each existing HMA Common Share will be
converted into the right to receive 0.06942 CYH Common Shares, 1 Community Health Systems, Inc. Series
A Contingent Value Right (CYHHZ), and $10.50 Cash. Cash will be paid in lieu of fractional CYH shares.
The Community Health Systems, Inc. Series A Contingent Value Rights will begin trading on the NASDAQ
Stock Market on January 27, 2014 under the trading symbol CYHHZ.
DISCLAIMER
This Information Memo provides an unofficial summary of the terms of corporate events affecting listed
options or futures prepared for the convenience of market participants. OCC accepts no responsibility for
the accuracy or completeness of the summary, particularly for information which may be relevant to
investment decisions. Option or futures investors should independently ascertain and evaluate all
information concerning this corporate event(s).
The determination to adjust options and the nature of any adjustment is made by a panel of The OCC
Securities Committee pursuant to OCC By-Laws, Article VI, Sections 11 and 11A. The adjustment panel is
comprised of representatives from OCC and each exchange which trades the affected option. The
determination to adjust futures and the nature of any adjustment is made by OCC pursuant to OCC By-
Laws, Article XII, Sections 3, 4, or 4A, as applicable. For both options and futures, each adjustment
decision is made on a case by case basis. Adjustment decisions are based on information available at the
time and are subject to change as additional information becomes available or if there are material
changes to the terms of the corporate event(s) occasioning the adjustment.
For CLEARING MEMBERS ARE REQUESTED TO IMMEDIATELY ADVISE ALL BRANCH OFFICES
ALL questions regarding this memo, call 1-888-678-4667 or email investorservices@theocc.com.
AND CORRESPOND
A lot of stuff with late start/openings in the Triad area. RDU and the Triangle to the east got more snow. We barely got an inch. So funny since I used to live in Upstate NY years ago and 12 - 18 inches may close schools, but everything else basically functioned. But then, like you, snow removal equipment is practically non-existent around here. Too bad it's not the weekend - mix good ol' boys, pickup trucks, alcohol and snow and you have lots of YouTube videos! "Lookit dis!!"
Quite a few things are closed in Columbia tomorrow. We only have 8 trucks available to fight snow and ice for the entire city and county.
Although I'm still trying to get used to winter weather, one good thing about living in the mid-South is when they get a light dusting of snow, they close up shop early!
With 57.8% 0f it's stock owned by strategic entities, according to Scottrade, ISSM may be one to watch. I have just started looking.
I'm very glad to say that I've got life by the tail and I'm pulling it hard.
Hi Salty, I am glad all is well and you are back posting again.
I am doing well and TY for asking. In addition to some computer problems I had some business out of town that kept me from posting.
Salty,how are you
I really don't know too much about WNDM but because you have it on your mind, I'll take a look too.
Good morning all, I've been trying to figure out what going on with
WNDM Wound Management I've only watch it go up, hate it when that happens. I was hoping for it to pullback, but yesterday 3x volume
20%^. Well anyway that just one I've been only waching.
http://ih.advfn.com/p.php?pid=nmona&article=60431140
http://www.otcmarkets.com/stock/WNDM/quote
Welcome to the board DITRstocks.
$HIMR Under water timber harvesting save trees and keeps out ecosystem intact. Every tree save give enough oxygen for 10 people.
http://otcnewsmagazine.com/in-pursuit-of-the-perfect-moment/
HIMR President Interview:
$MDCE Our planned products and/services also constitute a healthcare delivery and wellness site; dedicated to helping Chinese consumers live healthier, more balanced lives.
$MDCE Our main mission is to open and operate private children’s health & wellness clinics throughout China. Concurrent with, and in addition to the clinics we operate, it is our plan to add to our bottom revenue line by offering affordable, standardized and secure software information systems to electronically connect healthcare providers, academic institutions, pharmaceutical and nutraceutical companies, alternative health companies and individual consumers with healthcare information, products and services in China. We aim to generate e-management revenues and nutraceutical and pharmaceutical product distribution revenues.
Good morning Salty, Illegal,Joeysco and all.
AUXO looks like a good one to watch Gen.
Illegal, May be one to watch. AUXO 1.26
For the three months ended September 30, 2013, AUXILIO reported recurring service revenues increased by $1.3 million from existing and expanded contracts. Total revenues increased by approximately $2 million to $10.8 million, as compared to the same period in 2012. Equipment revenues were $1 million as compared to approximately $200,000 for the same period in 2012 due to copier fleet refresh activities at two customer accounts. Cost of revenues was $8.6 million for the three months ended September 30, 2013, as compared to $7.4 million for the same period in 2012. The increase is attributed to the service costs to support new and expanded recurring service contracts and the increase in new equipment placed. Gross profit for the third quarter of 2013 was $2.2 million or 21% of revenues, compared to $1.4 million or 15% of revenue for the same period of 2012. This improvement is a result of the increase in recurring service revenue and margin improvements from existing accounts.
Operating expenses for the third quarter of 2013 were $1.4 million, compared to $1.7 million in the same period of 2012. Net income for the third quarter of 2013 was $811,000 or $0.04 per share, compared to a net loss of $660,000 or $0.03 per share, in the same period of 2012. AUXILIO improved its non-GAAP measure of adjusted income from operations in the third quarter of 2013. Excluding $93,000 in charges related to stock based compensation, we achieved $950,000 or 9% of revenue compared to a loss of $180,000 or 2% of revenue after excluding charges of $92,000 related to stock-based compensation and $68,000 in charges related to stock granted for marketing activities, in the same period last year. We do not expect the non-GAAP measure of adjusted income from operations as a percent of revenue to stay this high over the next couple of quarters due to anticipated new account implementations.
For the Nine Months Ended September 30, 2013
For the nine months ended September 30, 2013, the company reported revenues of $31 million, an increase of 19% when compared to $26 million in the same period in 2012. Recurring service revenues increased 27% from new contracts and expanded contracts; however offsetting this increase were lower revenues from some accounts related to rate reductions from renewals. Cost of revenues was $25 million, as compared to $23 million for the same period in 2012. The increase in the cost of revenues is attributed primarily to staffing and service costs to support the new and expanded recurring service contracts. Gross profit for the first nine months of 2013 was $5.4 million, or 18% of revenues, compared to $3.1 million or 12% for the same period of 2012. Operating expenses for the first nine months of 2013 were $4.5 million, compared to $4.8 million in the same period of 2012. Net income for the first nine months of 2013 was $679,000, or $0.03 per share, compared to a net loss of $2.3 million or $0.12 per share, in the same period of 2012. After excluding charges of $409,000 related to stock-based compensation and $190,000 in charges related to stock granted for marketing activities, non-GAAP measure of adjusted income from operations for the nine months ended September 30, 2013 was $1.6 million or 5% of revenue compared to a loss of $1.1 million or 4% of revenue after excluding charges of $304,000 related to stock-based compensation and $272,000 in charges related to stock granted for marketing activities in the same period of 2012.
At September 30, 2013, our cash and cash equivalents were $3.1 million. During the nine months ended September 30, 2013, our cash provided by operating activities amounted to $1.1 million, as compared to $1.0 million used for operating activities for the same period in 2012. The improvement in cash provided by operating activities in 2013 is primarily a result of improved margins being generated from our recurring service revenue contracts. The cash used for operating activities for 2012 was primarily due to the costs incurred to implement new recurring service revenue contracts.
Paul Anthony, CFO of AUXILIO, stated: "This quarter marks a full year of positive adjusted income from operations. We attribute our strong financial performance to the number of new contracts and implementations executed over the last two years, and our ability to improve margins over time. Although we don't expect earnings to increase at the current rate due to on-boarding costs we expect to incur with anticipated new business growth, we feel our company is in a good position to absorb new accounts without compromising our ability to turn a profit."
Conference Call Information
Five Star Quality Care, Inc. (FVE) today announced certain preliminary financial data and information for the quarter and nine months ended September 30, 2013.
As described below, at this time we are not reporting income from continuing operations, income (loss) from discontinued operations, or net income because we recently discovered non-cash errors in our historical accounting accruals for income taxes in certain periods.
Third Quarter 2013 Financial Highlights:
Total revenues from continuing operations for the third quarter of 2013 increased 9.3% to $324.7 million from $297.1 million for the same period in 2012. Our senior living revenues and management fee revenues from continuing operations for the third quarter of 2013 increased 1.1% to $272.7 million from $269.9 million for the same period in 2012.
Earnings from continuing operations before interest, taxes, depreciation and amortization, or EBITDA from continuing operations, for the third quarter of 2013 was $9.3 million compared to $12.1 million for the same period in 2012. EBITDA from continuing operations excluding certain items was $10.0 million and $12.1 million for the third quarters of 2013 and 2012, respectively. A reconciliation of income from continuing operations before income taxes determined in accordance with U.S. generally accepted accounting principles, or GAAP, to EBITDA from continuing operations and EBITDA from continuing operations excluding certain items for the quarters ended September 30, 2013 and 2012 appears later in this press release.
Income from continuing operations before income taxes for the third quarter of 2013 was $1.6 million, compared to $4.3 million for the same period in 2012. Income from continuing operations before income taxes for the third quarter of 2013 included a loss on early extinguishment of debt of $599,000.
Third Quarter 2013 Operating Highlights (continuing operations):
Occupancy at our owned and leased senior living communities for the third quarter of 2013 was 85.9% compared to 86.2% for the same period in 2012.
The average monthly rate at our owned and leased senior living communities for the third quarter of 2013 increased by 1.5% to $4,411 from $4,345 for the same period in 2012.
The percentage of revenues derived from residents’ private resources at our owned and leased senior living communities for the third quarter of 2013 increased 50 basis points to 77.1% from 76.6% for the same period in 2012.
Year to Date Financial Highlights:
Total revenues from continuing operations for the nine months ended September 30, 2013 increased 9.9% to $972.0 million from $884.8 million for the same period in 2012. Our senior living revenues and management fee revenues from continuing operations for the nine months ended September 30, 2013 increased 1.0% to $815.8 million from $808.0 million for the same period in 2012.
EBITDA from continuing operations for the nine months ended September 30, 2013 was $30.3 million compared to $38.0 million for the same period in 2012. EBITDA from continuing operations excluding certain items was $31.0 million and $34.6 million for the nine months ended September 30, 2013 and 2012, respectively. A reconciliation of income from continuing operations before income taxes determined in accordance with GAAP to EBITDA from continuing operations and EBITDA from continuing operations excluding certain items for the nine months ended September 30, 2013 and 2012 appears later in this press release.
Income from continuing operations before income taxes for the nine months ended September 30, 2013 was $7.2 million compared to $15.6 million for the same period in 2012. Income from continuing operations before income taxes for the nine months ended September 30, 2013 included a loss on early extinguishment of debt of $599,000. Income from continuing operations before income taxes for the nine months ended September 30, 2012
VCHSX - VALIC Health Sciences fund. For those of you who also keep funds in either retirement portfolios (I have a "healthy" does in mine) or mutual funds in your taxable accounts.
http://quotes.morningstar.com/fund/VCHSX/f?t=VCHSX
403b version - http://www2.valic.com/valic/valic.nsf/images/profiles/$file/fp73.pdf
How insurance industry will profit from Obamacare from Barron's: http://online.barrons.com/article/SB50001424053111903533504579095103832318872.html
Remember, Obamacare is not healthcare reform, but health insurance reform.
A colleague of mine pointed out that a big part of Obamacare is based on preventative care, so we should look there as well.
For those who view Obamacare as being bent over the table and taking it up the shorts, be assured that your colonoscopy is a covered expense!
Interesting article. TY for posting it.
Nonprofits launching for-profit health plans. FYI, since there isn't any opportunity here, but just indicative of how things are changing under Obamacar - http://philanthropynewsdigest.org/news/nonprofit-health-centers-launching-for-profit-medicaid-plans
Hi, been extremely busy in this thing call "work".
Well, if they're gonna put you in a Rolls then they're certainly worthy of further examination!
I'm planning on KBLB and ASNB putting me into a new Rolls.
Anything stirring over here y'all, any promising leads?!
Close call! But exciting 4th qtr. I'm glad the real FSU showed up in the 3rd qtr for play. The FSU flag flies proudly from our porch in a neighborhood full of ACC fans.
WNDM
Company Background
Wound Management Technologies, Inc. (WMT) is engaged in developing and marketing products for the advanced wound care market, as pursued through the Company's wholly owned subsidiary, Wound Care Innovations, LLC (WCI), which brings a mix of products and procedures to the wound care arena. The patented collagen fragments (CRX) of CellerateRX are a fraction of the size of the native collagen molecules and particles found in other products. CellerateRX is cleared by the food and drug administration (FDA) as a medical device for use on all acute and chronic wounds, except third degree burns, and is ready for distribution in both gel and powder form. Manufacturing of the Company's products is conducted by Applied Nutritionals, LLC (Applied Nutritionals), which owns the CellerateRX trademark. During the year ended December 31, 2011, its warehousing, shipping, and physical inventory management were outsourced to Pac-Source, LLC of Roches. On December 29, 2011, WMT sold Secure eHealth, LLC.
http://www.wmgtech.com
BONU might be one to consider for a quick flip.
Company Background
BioNeutral Group, Inc. is a life science specialty technology company. The Company is a specialty chemical company that focuses on developing and commercializing a combinational chemistry based technology, which can neutralize harmful environmental contaminants, toxins and dangerous micro-organisms, including bacteria, viruses and spores. The Company's business operations are conducted through BioNeutral Laboratories Corporation USA (BioLabs). The Company is focused on commercializing two classes of product formulations: antimicrobials, which are formulations designed to kill certain harmful microscopic living organisms, and bioneutralizers, which are formulations designed to destroy certain agents that are noxious and harmful to health and/or the environment. As of October 31, 2012, the Company is focusing its efforts on the commercialization of its Ygiene formulation for use as a high-level cleansing.
http://www.bioneutral.com
The Noles rose to the occasion. Super Game!
PAWS just might be a good one. I just took a quick glance. Will look a little more later tonight.
I've heard of PAWS but never really paid attention to it. TY for reminding me of it.
Salty, I am watching this stock I would like to see last quarters earnings. I do not own shares.
The PAWS Pet Company, Inc. to implement In-Office Dispensing Program. Expects revenues to exceed $50M in 2014
PALO ALTO, CA, Nov. 26, 2013 /PRNewswire via COMTEX/ -- The PAWS Pet Company, Inc. (OTCQB:PAWS), is pleased to announce that it intends to begin implementation of its In-Office Dispensing Program (IODP) during the first half of December 2013 through our Advanced Access Pharmacy Services, LLC (AAPS) subsidiary. Our director, Evon Midei, will head this program up. Evon has forty years of experience in the medical industry including managing pharmacies and hospitals, having served as the COO and acting CEO of St. Luke's Hospital (formerly Allentown Osteopathic Medical Center) in Allentown, Pennsylvania. Evon holds a BS in Pharmacy and an MBA from Temple University.
Our IODP program has been designed to provide physicians the ability to prescribe and dispense medicines in-office, allowing patients to obtain diagnoses and prescriptions in one visit.
AAPS expects positive cash flow within the second quarter of 2014 with high margins. AAPS estimates that the potential revenues from this program could exceed $50 Million per year with a clear path to much higher revenues in the very near future.
In further news, the company is preparing the necessary documentation to change its name to Praxsyn Corporation and hopes to have all necessary documents filed with the all state, federal and nongovernmental agencies within the next ten to twenty days.
Work continues to finalize our agreement to acquire Mesa Pharmacy Inc. and our application for a California Community Pharmacy License is mostly complete, primarily waiting on the completion of our name change.
About The PAWS Pet Company, Inc.
The PAWS Pet Company, Inc. is undergoing a transition from the pet space to the pharmaceutical space. This exciting transition strategy has been developed to take advantage of the changes underway in traditional medical services. PAWS believes that great opportunities exist in pharmaceuticals and how they are delivered to the public.
For more information on The PAWS Pet Company go to: www.thepawspetcompany.com
Forward-Looking Statements
Certain statements made in this press release are forward-looking in nature (within the meaning of the Private Securities Litigation Reform Act of 1995) and, accordingly, are subject to risks and uncertainties. The actual results may differ materially from those described or contemplated and consequently, you should not rely on these forward-looking statements as predictions of future events. Certain of these risks and uncertainties are discussed in the reports we filed with the SEC.
SOURCE The PAWS Pet Company, Inc.
BZNE
MusclePharm Completes Acquisition of Substantially All Assets of BioZone Pharmaceuticals
Transaction Enhances MusclePharm's R&D, Manufacturing Capabilities
DENVER, CO--(Marketwired - Jan 6, 2014) - MusclePharm Corporation (OTCQB: MSLP), a leading international, award-winning sports nutrition company, today announced that it has completed the acquisition of essentially all assets of BioZone Pharmaceuticals, Inc. (OTCBB: BZNE) and its subsidiaries, for 1.2 million shares of MusclePharm stock.
Under the terms of the agreement, MusclePharm, through a newly formed Nevada subsidiary, BioZone Laboratories Inc., has acquired BioZone's manufacturing facility in Richmond, California; all assets associated with BioZone's QuSomes®, HyperSorb™ and EquaSome™ technologies; BioZone's Baker-Cummins line of products; and, the name "BioZone".
"We believe that BioZone is a complementary fit for MusclePharm, providing substantial opportunities to further enhance our science and quality control systems, as well as advance our innovation capabilities, which will add sophistication to the sports nutrition market," said Brad Pyatt, chief executive officer of MusclePharm. "We also believe that it gives us a long-term roadmap to eventually take control of our manufacturing and allow MusclePharm to be a fully-integrated company."
BioZone's patented QuSomes® technology enhances the absorption of topical and other drugs. MusclePharm is evaluating the QuSomes® technology to determine if the combination of QuSomes® and nutritional supplements could enhance the absorption and speed-of-delivery in several MusclePharm products.
MusclePharm's management believes that the acquisition will provide MusclePharm with the following additional benefits:
• An opportunity to bring science, innovation and sophistication to the sports nutrition market;
• The ability to realize meaningful cost savings by utilizing the existing BioZone facilities in Northern California to establish a new West Coast distribution center for MusclePharm products;
• An opportunity to realize substantial cost savings by internalizing and consolidating MusclePharm's product quality control programs, which are currently being outsourced; and
• Over time, the ability to internalize various manufacturing components of MusclePharm products.
Separately, more than a majority of the shareholders of BioZone approved the transaction. Valuation Research Corporation ("VRC") provided the fairness opinion in connection with the transaction to MusclePharm's Strategic Committee comprised of the independent members of its board of directors.
About MusclePharm Corporation
MusclePharm® is a leading international, award-winning sports nutrition company offering vitamins and nutritional supplements which are available in more than 110 countries and available in 35,000+ retail outlets, including Costco, Dick's Sporting Goods, 24 Hour Fitness, Bally's, GNC, Vitamin Shoppe and Vitamin World. The company's brands are MusclePharm®, Arnold Schwarzenegger™ Series, and FitMiss™. The comprehensive lines of clinically-proven, safe and effective nutritional supplements are developed through a six-stage research process that utilizes the expertise of leading nutritional scientists, doctors and universities. For more information, visit www.musclepharmcorp.com . Follow the company at http://www.facebook.com/MusclePharm and www.Twitter.com/MusclePharm .
FORWARD-LOOKING STATEMENTS
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects", "anticipates", "intends", "estimates", "plans", "potential", "possible", "probable", "believes", "seeks", "may", "will", "should", "could" or the negative of such terms or other similar expressions. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the Company's business. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2012, the Company's Quarter Reports on Form 10-Q and other filings submitted by the Company to the SEC, copies of which may be obtained from the SEC's website at www.sec.gov . Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and the Company undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.
For more information, contact:
Matt Sheldon/Evan Pondel
PondelWilkinson Inc.
(310) 279-5980
Email Contact
ASNB
Company Background
AdvanSource Biomaterials Corporation (AdvanSource) develops advanced polymer materials which provide critical characteristics in the design and development of medical devices. The Company's biomaterials are used in devices that are designed for treating a broad range of anatomical sites and disease states. The Company's technology, notably products, such as ChronoFlex, ChronoSil, HydroMed, and HydroThane, has been developed to overcome a wide range of design and functional challenges, from the need for dimensional stability, ease of manufacturability and demanding physical properties to overcoming environmental stress cracking and providing heightened lubricity for ease of insertion.
http://www.advbiomaterials.com
Good morning yall. Time to hop out of the sack and make the first trading day of the new year a muy profitable one, Let's get up and do it!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
illegal,
I do own shares of GATA but I do not have that much invested.The problem I have with pink sheet stocks is a company can do a reverse stock split with out shareholders even voting.
Serving India and South East Asia, Groupe Athena has been serving companies abroad in obtaining FDA approval for pharmaceuticals, medical products and devices for export to America. Our goal is to ensure each of our clients passes FDA inspection by assisting them from concept through development, with consultation through all the regulatory requirements, filings, and processes to achieve FDA compliance and approval.
With offices in India and America, the expert consultants of Groupe Athena are in position to go to target companies in Asia and the regulatory authorities in the USA directly, consulting with our clients in the East to serve them completely in providing consultancy services for FDA compliance. Services include providing technical and regulatory consulting for biotechnical products, pharmaceuticals [over the counter, prescription and generics], diagnostics, medical equipment, and devices.
The FDA inspection process is traditionally complicated, especially for foreign drug and medical companies trying to export to the USA. With broad spectrum consultancy and assistance through this process, our client base can count on reduced risk, follow-through on steps necessary for FDA compliance and identifying and solving breaches in compliance.
From concept through final approval, Groupe Athena navigates companies through every requirement of the process including pharmaceutical consulting, development, and regulatory compliance to achieve FDA approval and export pharmaceuticals and medical products and equipment to the USA.
A safe and Happy New Year to everyone. Don't drink all your 2013 profits tonight - you'll need the money for bargain hunting in 2014!
TY very much Gen. LBMH is another interesting find with a lot of potential.
LBMH
Liberator Medical Reports Revenue of $69 Million for Its Fiscal Year Ended September 30, 2013
The Company Reports Net Income of $7 Million, or $0.14 per Share, for the Year
Followers
|
3
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
130
|
Created
|
12/16/13
|
Type
|
Premium
|
Moderator illegal_alias | |||
Assistants |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |